NCI-H1666細胞
ATCC Number： CRL-5885?
相關**： 其他**
細胞形態： 其他
年限： 50 years
是否是腫瘤細胞： 1
物種來源： 人
生長狀態： 貼壁生長
器官來源： 肺
運輸方式： 凍存運輸
數量： 大量
Designations: NCI-H1666 [H-1666, H1666]
Depositors: AF Gazdar, JD Minna
NCI-H1666細胞Biosafety Level: 1
Shipped: frozen
Medium & Serum: See Propagation
Growth Properties: loosely adherent
Organism: Homo sapiens
Morphology: epithelial (many rounded cells)
Source: Organ: lung
Disease: adenocarcinoma; bronchoalveolar carcinoma
Derived from metastatic site: pleural effusion
Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
Restrictions: NCI-H1666細胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.
Isolation: Isolation date: June, 1987
DNA Profile (STR): Amelogenin: X
CSF1PO: 11
D13S317: 15
D16S539: 13
D5S818: 10
D7S820: 8,11
THO1: 8,9.3
TPOX: 11
vWA: 16,17
GenoType: EGFR (wt) [90471]
Age: 50 years
Gender: female
Ethnicity: NCI-H1666細胞Caucasian
Comments: The line was established in June 1987.
The patient received prior radiation therapy.
The tissue donor was a non-smoker.
Propagation: ATCC complete growth medium: ACL-4 medium (serum-free)
The base medium for this cell line is ATCC formulated DMEM: F12 Medium Catalog No. 30-2006. To make the complete growth medium, add the following components to the base medium:
0.02 mg/ml insulin
0.01 mg/ml transferrin
25 nM sodium selenite (final conc.)
50 nM Hydrocortisone (final conc.)
1 ng/ml Epidermal Growth Factor (do not filter)
0.01 mM ethanolamine (final conc.)
0.01 mM phosphorylethanolamine (final conc.)
100 pM triiodothyronine (final conc.)
0.5% (w/v) bovine serum albumin (final conc.)
0.5 mM sodium pyruvate (final conc.)
extra 2mM L-glutamine (for final conc. of 4.5mM)
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Subculturing: NCI-H1666細胞Protocol:
Remove and discard culture medium.
Briefly rinse the cell layer with 0.25% (w/v) Trypsin- 0.53 mM EDTA solution.
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37?C to facilitate dispersal.
Add 6.0 to 8.0 ml of complete growth medium and aspirate cells by gently pipetting.
To remove trypsin-EDTA solution, transfer cell suspension to centrifuge tube and spin at approximately 125 xg for 5 to 10 minutes.Discard supernatant and resuspend cells in fresh growth medium. Add appropriate aliquots of cell suspension to new culture vessels.
Incubate cultures at 37?C.
Subcultivation Ratio: A subcultivation ratio of 1:2 to 1:4 is recommended
Preservation: Freeze medium: Complete growth medium supplemented with 10% fetal bovine serum and 5% DMSO
Storage temperature: liquid nitrogen vapor phase
Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2006
References: 23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..
90471: Sordella R, et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004. PubMed: 15284455
